Cited by 1,598Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Open access

Bean, James, Brennan, Cameron, Shih, Jin-Yuan, Riely, Gregory, Viale, Agnes, Wang, Lu, Chitale, Dhananjay, Motoi, Noriko, Szoke, Janos, Broderick, Stephen, Balak, Marissa, Chang, Wen-Cheng, Yu, Chong-Jen, Gazdar, Adi, Pass, Harvey, Rusch, Valerie, Gerald, William, Huang, Shiu-Feng, Yang, Pan-Chyr, Miller, Vincent, Ladanyi, Marc, Yang, Chih-Hsin, Pao, William·2007·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0710370104PMC PMC2409244

Open this paper in CoChat — free account

Abstract

In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib. To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance. Among three loci demonstrating recurrent copy number alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene. Collectively, analysis of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test). Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFR(T790M) mutation. We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addition to a drug-sensitive EGFR mutation and the T790M change. Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET. Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.

Integrity signals

Registry

Crossref · 10.1073/pnas.0710370104

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Circular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,304
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Show all 37 references

Research works printed but not linked: 1

BA Weir, MS Woo, G Getz, S Perner, L. Ding, R Beroukhim, WM Lin, MA Province, A Kraja, L Johnson, et al. Nature, 10.1038. (2007).

Sorted by citations

Items 701–800 of 1,001

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer
Lara-Guerra, H., Chung, C. T. ‐., Schwock, J., Pintilie, M., Hwang, D. M., Leighl, N. B., Waddell, T. K., & Tsao, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.020 · Cited by 38
Insertions and Deletions (Indels)
Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00009-5 · Cited by 49
Onartuzumab in lung cancer: the fall of Icarus?
Rolfo, C. D., Steen, N. V. D., Pauwels, P., & Cappuzzo, F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1031219 · Cited by 38
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
Savonarola, A., Palmirotta, R., Guadagni, F., & Silvestris, F. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.28 · Cited by 36
Identification of driver mutations in lung cancer: first step in personalized cancer
Planchard, D. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0263-z · Cited by 38
The C-terminus of Hsp70-Interacting Protein Promotes Met Receptor Degradation
Jang, K. W., Lee, J. E., Kim, S. Y., Kang, M., Na, M. H., Lee, C. S., Song, K. S., & Lim, S. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d9c7e · Cited by 37
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Ariyawutyakorn, W., Saichaemchan, S., & Varella‐Garcia, M. (2016) · Journal of Cancer · doi:10.7150/jca.12663 · Cited by 37
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
Gou, L.-Y., Li, A., Yang, J., Zhang, X., Su, J., Yan, H., Xie, Z., Lou, N.-N., Liu, S. M., Dong, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9697 · Cited by 39
(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer
Siddique, A. B., Kilgore, P. C. S. R., Tajmim, A., Singh, S. S., Meyer, S. A., Jois, S. D. S., Cvek, U., Trutschl, M., & Sayed, K. A. E. (2020) · Nutrients · doi:10.3390/nu12061749 · Cited by 37
NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
Michelotti, A., de Scordilli, M., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126748 · Cited by 37
Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells
Somwar, R., Shum, D., Djaballah, H., & VARMUS, H. E. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109350919 · Cited by 37
Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer
Sharma, R., & Malviya, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188869 · Cited by 35
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
Nurwidya, F., Takahashi, F., Murakami, A., Kobayashi, I., Kato, M., Shukuya, T., Tajima, K., Shimada, N., & Takahashi, K. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.07.007 · Cited by 37
Biological challenges of BRAF inhibitor therapy
Puzanov, I. J., Burnett, P., & Flaherty, K. T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.005 · Cited by 38
Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?
Tsai, C., Chen, J., Stewart, D. J., Chiu, C., Lai, C.-L., Hsiao, S.-Y., Chen, Y.-M., & Chang, K.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182021ff5 · Cited by 36
MicroRNA‐181b‐5p, ETS1, and the c‐Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy
Tomihara, H., Yamada, D., Eguchi, H., Iwagami, Y., Noda, T., Asaoka, T., Wada, H., Kawamoto, K., Gotoh, K., Takeda, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13159 · Cited by 36
Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer
Gkolfinopoulos, S., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.28 · Cited by 37
Cancer Immunotherapy: The Dawn of Antibody Cocktails
Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36
Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors
Esaki, T., Hirai, F., Makiyama, A., Seto, T., Bando, H., Naito, Y., Yoh, K., Ishihara, K., Kakizume, T., Natsume, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13956 · Cited by 36
Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
Xu, H., Shen, J., Xiang, J., Li, H., Li, B., Zhang, T., Zhang, L., Mao, X., Jian, H., & Shu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s197337 · Cited by 36
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
Antiproliferative, Cell-Cycle Dysregulation Effects of Novel Asiatic Acid Derivatives on Human Non-small Cell Lung Cancer Cells
Wang, L., Xu, J., Zhao, C., Zhao, L., & Feng, B. (2013) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c13-00328 · Cited by 36
Self-citation
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Michels, S. Y. F., Heydt, C., van Veggel, B. A. M. H., Deschler-Baier, B., Pardo, N., Monkhorst, K., Rüsseler, V., Stratmann, J., Griesinger, F., Steinhauser, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00210 · Cited by 36
New molecular targeted therapies for advanced non-small-cell lung cancer.
Méndez, M., Custodio, A., & Provencio, M. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.03 · Cited by 34
Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer
Chen, H., Yan, H., Yang, J., Chen, Z., Su, J., Zhang, X., & Wu, Y.-L. L. C. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9651-z · Cited by 35
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
Asami, K., Okuma, T., Hirashima, T., Kawahara, M., Atagi, S., Kawaguchi, T., Okishio, K., Omachi, N., & Takeuchi, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.022 · Cited by 35
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
Landi, L. M., Tiseo, M., Chiari, R., Ricciardi, S., Rossi, E., Galetta, D., Novello, S., Milella, M., D’Incecco, A., Minuti, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.002 · Cited by 35
MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance
Kanteti, R., Yala, S., Ferguson, M. K., & Salgia, R. (2009) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v28.i2.10 · Cited by 35
Non-Antioxidant Properties of α-Tocopherol Reduce the Anticancer Activity of Several Protein Kinase Inhibitors In Vitro
Pédeboscq, S., Rey, C., Petit, M., Harpey, C., Giorgi, F. D., Ichas, F., & Lartigue, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036811 · Cited by 36
Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET -Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Bachleitner‐Hofmann, T., Sun, M. Y., Chen, C., Liska, D., Zeng, Z., Viale, A. J., Olshen, A. B., Mittlboeck, M., Christensen, J. G., Rosen, N. X., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0253 · Cited by 35
Self-citation
c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer
Arulappu, A., Battle, M. R., Eisenblätter, M., McRobbie, G., Khan, I. A., Monypenny, J., Weitsman, G. E., Galazi, M., Hoppmann, S., Gazińska, P., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164384 · Cited by 35
Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor
Zhan, Z., Xia, P., Liu, Q., Chen, F., Ji, Y., Yao, S., Xi, Y., Lin, Y., Chen, T., Xu, Y., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.076 · Cited by 35
Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment
Ni, Y., Bi, J., Ye, X., Fan, W., Yu, G., Yang, X., Huang, G., Li, W., Wang, J., Han, X., et al. (2016) · Medicine · doi:10.1097/md.0000000000003998 · Cited by 35
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Xue, Y., Hou, S., Ji, H., & Han, X. (2016) · Protein & Cell · doi:10.1007/s13238-016-0330-1 · Cited by 35
c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications
Hass, R., Jennek, S., Yang, Y., & Friedrich, K. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0165-2 · Cited by 35
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Yang, Z., Zhang, S., Hu, X., & Tam, K. Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.016 · Cited by 35
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
Lee, M. H., Jain, P., Wang, F., Ma, P. C., Borczuk, A., & Halmos, B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1925648 · Cited by 35
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment
Sudhindra, A., Ochoa, R. E., & Santos, E. S. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.02.003 · Cited by 34
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
Kanda, S., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Kubota, K., Tamura, T., & Ohe, Y. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.016 · Cited by 34
JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor
Zhang, F., Yang, W., Duan, S., Xia, Y., Zhu, R., & Chen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3685 · Cited by 34
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis
Han, C., Ma, J.-T., Li, F., Zhao, J., Wei, J., Zhou, Y., & Zou, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.012 · Cited by 33
Targeting c-MET in the battle against advanced nonsmall-cell lung cancer
Landi, L. M., Minuti, G., D’Incecco, A., & Cappuzzo, F. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835daf37 · Cited by 34
Treatment of nonsmall cell lung cancer
Carter, C. A., & Giaccone, G. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834ec6a7 · Cited by 34
A systematic approach to therapeutic target selection in oesophago-gastric cancer
Paterson, A., Shannon, N. B., Lao‐Sirieix, P., Ong, C. J., Peters, C. J., O’Donovan, M., & Fitzgerald, R. C. (2012) · Gut · doi:10.1136/gutjnl-2012-302039 · Cited by 34
Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
Mellinghoff, I. K., Lassman, A. B., & Wen, P. Y. (2011) · Glia · doi:10.1002/glia.21137 · Cited by 34
Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling
Yuen, H., Chan, K.-K., Platt-Higgins, A. M., Dakir, E.-H., Matchett, K. B., Haggag, Y. A., Jithesh, P. V., Habib, T., Faheem, A., Fennell, D. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12420 · Cited by 34
Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells
Zhang, L., Feng, Z., Su, M., Jiang, X., Chen, X., Wang, Y., Li, A., Lin, L., & Lu, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.020 · Cited by 34
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Baldacci, S., Kherrouche, Z., Cockenpot, V., Stoven, L., Copin, M. C., Werkmeister, E., Marchand, N., Kyheng, M., Tulasne, D., & Cortot, A. B. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.008 · Cited by 34
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wang, W., Wang, H., Lu, P., Yu, Z., Xu, C., Zhuang, W., & Song, Z. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1803-9 · Cited by 34
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
McCoach, C. E., Yu, A., Gandara, D. R., Riess, J. W., Vang, D. P., Li, T., Lara, P. N., Gubens, M. A., Lara, F., Mack, P. C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00279 · Cited by 34
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model
Hayakawa, H., Ichihara, E., Ohashi, K., Ninomiya, T., Yasugi, M., Takata, S., Sakai, K., Matsumoto, K., Takigawa, N., Tanimoto, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12284 · Cited by 36
The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
Olayan, A. A., Hussaini, H. A., & Jazieh, A. R. (2012) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2012.09.004 · Cited by 36
Antibody–drug conjugates for lung cancer in the era of personalized oncology
Ricciuti, B., Lamberti, G., Andrini, E., Genova, C., Giglio, A. D., Bianconi, V., Sahebkar, A., Chiari, R., & Pirro, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.024 · Cited by 35
Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC
Yu, Y., Abudula, M., Li, C., Chen, Z., Zhang, Y., & Chen, Y. (2019) · Respiratory Research · doi:10.1186/s12931-019-1202-z · Cited by 33
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.
Sacco, J. J., & Clague, M. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.03.05 · Cited by 33
High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer
Feng, Y., Minca, E. C., Lanigan, C. P., Liu, A., Zhang, W., Yin, L., Pennell, N. A., Farver, C. F., Tubbs, R., & Ma, P. C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000145 · Cited by 33
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells
Boccaccio, C., Luraghi, P., & Comoglio, P. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1088 · Cited by 34
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation
Owusu, B. Y., Thomas, S., Venukadasula, P. K. M., Han, Z., Janetka, J. W., Galemmo, R. A., & Klampfer, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18260 · Cited by 33
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 36
Immunotherapeutic progress and application of bispecific antibody in cancer
Kang, J., Sun, T., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020003 · Cited by 37
Met interacts with EGFR and Ron in canine osteosarcoma
McCleese, J., Bear, M. D., Kulp, S. K., Mazcko, C. N., Khanna, C., & London, C. A. (2011) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2011.00309.x · Cited by 33
Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met
Northrup, A. B., Katcher, M. H., Altman, M. D., Chénard, M., Daniels, M. H., Deshmukh, S. V., Falcone, D., Guerin, D. J., Hatch, H., Li, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301619u · Cited by 33
Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis
Lee, J., Li, C., Fang, F., Wang, J.-W., Jeng, Y., Yu, S. C., Lin, Y.-T., Wu, J.-M., Tsai, J., Li, S.-H., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.128 · Cited by 33
The MET axis as a therapeutic target
Sattler, M., & Salgia, R. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2009.01.001 · Cited by 33
The Role of Pathologists in the Era of Personalized Medicine
Walk, E. E. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.605 · Cited by 33
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)
Ugolini, A., Kenigsberg, M., Rak, A., Vallée, F., Houtmann, J., Lowinski, M., Capdevila, C., Khider, J., Albert, E., Martinet, N., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00280 · Cited by 33
Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Meador, C. B., Jin, H., de Stanchina, E., Nebhan, C. A., Pirazzoli, V., Wang, L., Wang, L., Vuong, H., Hutchinson, K. E., Jia, P., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0723 · Cited by 31
Self-citation
Targetable “Driver” Mutations in Non Small Cell Lung Cancer
Vijayalakshmi, R., & Krishnamurthy, A. (2011) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-011-0108-0 · Cited by 33
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A., & Nakagawa, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys042 · Cited by 32
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation
Zhao, B.-X., Wang, J., Song, B., WEI, H., Lv, W., TIAN, L.-M., Li, M., & Lv, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3058 · Cited by 32
Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Voortman, J., Harada, T., Chang, R., Killian, J. K., Suuriniemi, M., Smith, W. I., Meltzer, P. S., Lucchi, M., Wang, Y., & Giaccone, G. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804547196 · Cited by 32
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
Apicella, M., Migliore, C., Capelôa, T., Menegon, S., Cargnelutti, M., Degiuli, M., Sapino, A., Sottile, A., Sarotto, I., Casorzo, L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.283 · Cited by 32
Histopathologic diagnosis of brain metastases: current trends in management and future considerations
Bekaert, L., Emery, É., Levallet, G., & Lechapt, E. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0275-3 · Cited by 32
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Baldacci, S., Mazières, J., Tomasini, P., Girard, N., Guisier, F., Audigier-Valette, C., Monnet, I., Wislez, M., Pérol, M., Dô, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21707 · Cited by 32
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway
Ni, J., Zhou, L., Ding, L., Zhao, X., Cao, H., Fan, F., Li, H., Lou, R., Du, Y., Dong, S., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.10.024 · Cited by 32
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
Yamamoto, S., Tsuda, H., Miyai, K., Takano, M., Tamai, S., & Matsubara, O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.143 · Cited by 32
Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization–tandem mass spectrometry (LC-ESI–MS/MS)
Roberts, M. S., Turner, D. C., Broniscer, A., & Stewart, C. F. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.04.035 · Cited by 32
The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
Medová, M., Pochon, B., Streit, B., Blank-Liss, W., Francica, P., Stroka, D., Keogh, A., Aebersold, D. M., Blaukat, A., Bladt, F., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0151 · Cited by 32
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
Hong, D. S., Rosen, P. J., Lockhart, A. C., Fu, S., Jankú, F., Kurzrock, R., Khan, R. S., Amore, B. M., Caudillo, I., Deng, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4472 · Cited by 32
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
Meniawy, T. M., Lake, R., McDonnell, A. M., Millward, M., & Nowak, A. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.006 · Cited by 31
MEK inhibitors against MET-amplified non-small cell lung cancer
Chiba, M., Togashi, Y., Tomida, S., Mizuuchi, H., Nakamura, Y., Banno, E., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3736 · Cited by 32
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
Nakata, A., & Gotoh, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.697155 · Cited by 31
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
Chung, C. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215577810 · Cited by 31
3′-Deoxy-3′-18F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-xL Inhibitors in Non–Small Cell Lung Cancer
Zannetti, A., Iommelli, F., Speranza, A., Salvatore, M., & Vecchio, S. D. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096503 · Cited by 31
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice
Steeghs, E. M. P., Groen, H. J. M., Schuuring, E. M. D., Aarts, M. J., Damhuis, R. A. M., Voorham, Q. J. M., Ligtenberg, M. J. L., & Grünberg, K. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.04.001 · Cited by 32
Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients
Lewandowska, M. A., Jóźwicki, W., Jochymski, C., & Kowalewski, J. (2013) · Oncology Reports · doi:10.3892/or.2013.2579 · Cited by 32
NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells
Choi, B.-H., Ryu, D. Y., Ryoo, I.-G., & Kwak, M. (2017) · Oncotarget · doi:10.18632/oncotarget.22513 · Cited by 32
Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
Solomon, B., & Pearson, R. B. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a74dba · Cited by 32
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Hu, B., Wiesehöfer, M., de Miguel, F. J., Liu, Z. Z., Chan, L.-H., Choi, J., Melnick, M. A., Estape, A. A., Walther, Z., Zhao, D., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-0438 · Cited by 29
Targeting the Met pathway in lung cancer
Belalcazar, A., Azaña, D., Perez, C. A., Raez, L. E., & Santos, E. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.16 · Cited by 30
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
Zapater, E. O., Lee, R. W., Owen, W. J., Weitsman, G. E., Fruhwirth, G. O., Dunn, R. G., Neat, M. J., McCaughan, F. M., Parker, P. J., Ng, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170798 · Cited by 30
Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
Oronsky, B. T., Ma, P., Reid, T. R., Cabrales, P., Lybeck, M., Oronsky, A. L., Oronsky, N. C., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.11.001 · Cited by 30
Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer
Huang, J., Duan, L.-X., Liu, Q., Li, H.-F., Hu, A.-P., Song, J., Lin, C., Huang, B., Yao, D., Peng, B., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02645-2 · Cited by 32
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Bertoli, E., Carlo, E. D., Basile, D., Zara, D., Stanzione, B., Schiappacassi, M., Conte, A. D., Spina, M., & Bearz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310803 · Cited by 34

Authors: Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., Balak, M., Chang, W.-C., Yu, C.-J., Gazdar, A., Pass, H., Rusch, V., Gerald, W., Huang, S.-F., Yang, P.-C., Miller, V., Ladanyi, M., Yang, C.-H., & Pao, W.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
National Taiwan University (TW)
Department of Pathology, Memorial Sloan–Kettering Cancer Center, New York, NY 10021;
Chang Gung Memorial Hospital (TW)
The University of Texas Southwestern Medical Center (US)
NYU Langone Health (US)
National Health Research Institutes (TW)
National Taiwan University Hospital (TW)
ORCID: Bean, James
Brennan, Cameron
Shih, Jin-Yuan
Riely, Gregory
Viale, Agnes
Wang, Lu
Chitale, Dhananjay
Motoi, Noriko
Broderick, Stephen
Yu, Chong-Jen
Gazdar, Adi
Pass, Harvey
Rusch, Valerie
Huang, Shiu-Feng
Yang, Pan-Chyr
Miller, Vincent
Ladanyi, Marc
Pao, William
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2007-12-26
Volume: 104
Issue: 52
Pages: 20932-20937
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0710370104
PMC: PMC2409244
OpenAlex: W2093613683
Cited by: 1,598
References: 37
Citations by year: 2026: 17 · 2025: 19 · 2024: 33 · 2023: 42 · 2022: 59 · 2021: 54 · 2020: 78 · 2019: 78 · 2018: 100 · 2017: 89 · 2016: 116 · 2015: 135 · 2014: 124 · 2013: 148 · 2012: 126
FWCI: 71.72
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Conquer Cancer Foundation
Memorial Sloan-Kettering Cancer Center
Exelixis
National Cancer Institute (U01 CA 84999, P50CA75907, R01CA121210, U01CA084999, K08CA097980, R21CA115051)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, T790M mutation, EGFR mutation, lung adenocarcinoma, acquired drug resistance, gefitinib, erlotinib, EGFR tyrosine kinase inhibitors, copy number alterations, multikinase inhibitor, therapeutic target
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Proto-Oncogene Mas, Adenocarcinoma, Antineoplastic Agents, Chromosomes, Human, Pair 7, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Quinazolines, Cohort Studies, Gene Expression Regulation, Neoplastic, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks